Severe Hypocalcemia and Dramatic Increase in Parathyroid Hormone after Denosumab in a Dialysis Patient: A Case Report and Review of the Literature
المؤلفون المشاركون
Bhat, Zeenat
Bhanot, Ravinder Datt
Kaur, Jasleen
المصدر
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-4، 4ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-03-21
دولة النشر
مصر
عدد الصفحات
4
التخصصات الرئيسية
الملخص EN
Chronic kidney disease-mineral and bone disorder (CKD-MBD) is frequently present in advanced stages of chronic kidney disease (CKD) patients with high risk of fracture and elevated socioeconomic burden.
Denosumab, an injectable human monoclonal antibody with affinity for nuclear factor-kappa ligand (RANKL), is an effective treatment for osteoporosis in postmenopausal women and men.
Unlike the bisphosphonates, the pharmacokinetics and pharmacodynamics of denosumab are not influenced by the renal function and are being increasingly used for patients having CKD-MBD with low bone mineral density (BMD) to reduce the risk of fragility fractures.
Hypocalcemia is a known side effect of this drug along with compensatory increase in parathyroid hormone (PTH).
However, limited information is available in the literature regarding this potentially life-threatening side effect with denosumab in end-stage renal disease (ESRD) patients on dialysis.
We present a patient with ESRD on peritoneal dialysis who developed severe symptomatic hypocalcemia and dramatic increase in PTH following denosumab therapy.
She was conservatively managed with calcium supplementation and appropriate adjustment in calcium dialysate.
We have also reviewed the literature on the use of denosumab in dialysis patients and looked at additional factors that may precipitate severe hypocalcemia in these patients.
We believe that denosumab should be used with caution in dialysis patients since it may lead to profound hypocalcemia.
Clinicians should ensure special attention in recognizing patients at risk of developing this serious adverse effect, so that prompt treatment and preventive strategies can be implemented.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Bhanot, Ravinder Datt& Kaur, Jasleen& Bhat, Zeenat. 2019. Severe Hypocalcemia and Dramatic Increase in Parathyroid Hormone after Denosumab in a Dialysis Patient: A Case Report and Review of the Literature. Case Reports in Nephrology،Vol. 2019, no. 2019, pp.1-4.
https://search.emarefa.net/detail/BIM-1141073
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Bhanot, Ravinder Datt…[et al.]. Severe Hypocalcemia and Dramatic Increase in Parathyroid Hormone after Denosumab in a Dialysis Patient: A Case Report and Review of the Literature. Case Reports in Nephrology No. 2019 (2019), pp.1-4.
https://search.emarefa.net/detail/BIM-1141073
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Bhanot, Ravinder Datt& Kaur, Jasleen& Bhat, Zeenat. Severe Hypocalcemia and Dramatic Increase in Parathyroid Hormone after Denosumab in a Dialysis Patient: A Case Report and Review of the Literature. Case Reports in Nephrology. 2019. Vol. 2019, no. 2019, pp.1-4.
https://search.emarefa.net/detail/BIM-1141073
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1141073
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر